{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:10:05Z","timestamp":1792145405394,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.mayocp.2021.08.006","type":"journal-article","created":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T17:30:31Z","timestamp":1637343031000},"page":"261-273","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1016","volume":"97","author":[{"given":"Gonzalo","family":"Barge-Caballero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2572-2048","authenticated-orcid":false,"given":"Eduardo","family":"Barge-Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"L\u00f3pez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Bilbao-Quesada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gonz\u00e1lez-Babarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"G\u00f3mez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"L\u00f3pez-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Guti\u00e9rrez-Feijoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Varela-Rom\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gonz\u00e1lez-Juanatey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d3scar","family":"D\u00edaz-Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda G.","family":"Crespo-Leiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.mayocp.2021.08.006_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovi\u0107","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.mayocp.2021.08.006_bib2","first-page":"e7","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association [erratum appears in Circulation. 2021;144(1):e11]","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.mayocp.2021.08.006_bib3","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garc\u00eda-Pav\u00eda","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.mayocp.2021.08.006_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"11","key":"10.1016\/j.mayocp.2021.08.006_bib5","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/ejhf.1563","article-title":"Real-world versus trial patients with transthyretin amyloid cardiomyopathy","volume":"21","author":"Canepa","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.mayocp.2021.08.006_bib6","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1002\/ehf2.13411","article-title":"Current patterns of beta-blocker prescription in cardiac amyloidosis: an Italian nationwide survey","volume":"8","author":"Tini","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"24","key":"10.1016\/j.mayocp.2021.08.006_bib7","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Non-biopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.mayocp.2021.08.006_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"25","key":"10.1016\/j.mayocp.2021.08.006_bib9","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.mayocp.2021.08.006_bib10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1023\/A:1020363010465","article-title":"Using propensity scores to help design observational studies: application to the tobacco litigation","volume":"2","author":"Rubin","year":"2001","journal-title":"Health Serv Outcomes Res Methodol"},{"issue":"30","key":"10.1016\/j.mayocp.2021.08.006_bib11","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"issue":"27","key":"10.1016\/j.mayocp.2021.08.006_bib12","first-page":"2129","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure [erratum appears in Eur Heart J. 2018;39(10):860]","volume":"37","author":"Ponikowsky","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.mayocp.2021.08.006_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.ejheart.2004.02.003","article-title":"Effect of carvedilol on diastolic function in patients with diastolic heart failure and preserved systolic function: results of the Swedish Doppler-echocardiographic study (SWEDIC)","volume":"6","author":"Bergstrom","year":"2004","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.mayocp.2021.08.006_bib14","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jacep.2020.04.019","article-title":"Atrial fibrillation in transthyretin cardiac amyloidosis: predictors, prevalence and efficacy of rhythm control strategies","volume":"6","author":"Donnellan","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"issue":"1","key":"10.1016\/j.mayocp.2021.08.006_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.hrthm.2013.10.026","article-title":"Implantable cardioverter-defibrillator placement in patients with cardiac amyloidosis","volume":"11","author":"Varr","year":"2014","journal-title":"Heart Rhythm"},{"issue":"4","key":"10.1016\/j.mayocp.2021.08.006_bib16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/CIRCULATIONAHA.119.040129","article-title":"Different histopathological diagnoses in patients with clinically diagnosed hypertrophic cardiomyopathy after surgical myectomy","volume":"140","author":"Alashi","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mayocp.2021.08.006_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S1388-9842(02)00251-9","article-title":"Anti-oxidative properties of beta-blockers and angiotensin-converting enzyme inhibitors in congestive heart failure","volume":"5","author":"Chin","year":"2003","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.mayocp.2021.08.006_bib18","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jchf.2014.03.009","article-title":"Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis","volume":"2","author":"Dorbala","year":"2014","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.mayocp.2021.08.006_bib19","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"issue":"6","key":"10.1016\/j.mayocp.2021.08.006_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.phrs.2010.08.001","article-title":"Carvedilol treatment reduces transthyretin deposition in a familial amyloidotic polyneuropathy mouse model","volume":"62","author":"Macedo","year":"2010","journal-title":"Pharmacol Res"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621006248?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619621006248?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T01:08:37Z","timestamp":1644196117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619621006248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0025619621006248"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.08.006","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beta-Blocker Exposure and Survival in Patients With Transthyretin Amyloid Cardiomyopathy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2021.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}